Dyne Therapeutics (NASDAQ:DYN) Now Covered by Sanford C. Bernstein

Sanford C. Bernstein started coverage on shares of Dyne Therapeutics (NASDAQ:DYN) in a research note issued to investors on Tuesday morning, Marketbeat Ratings reports. The brokerage issued a market perform rating and a $13.00 target price on the stock.

Several other equities analysts also recently weighed in on the company. Oppenheimer assumed coverage on Dyne Therapeutics in a research report on Monday, June 2nd. They issued an “outperform” rating and a $34.00 target price on the stock. JPMorgan Chase & Co. cut their target price on Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating for the company in a research note on Friday, March 21st. Raymond James Financial started coverage on Dyne Therapeutics in a report on Wednesday, June 11th. They set an “outperform” rating and a $37.00 price target for the company. Scotiabank started coverage on shares of Dyne Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 price objective on the stock. Finally, HC Wainwright decreased their target price on shares of Dyne Therapeutics from $46.00 to $38.00 and set a “buy” rating on the stock in a research report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $41.87.

Dyne Therapeutics Stock Performance

DYN stock opened at $10.63 on Tuesday. The firm’s fifty day moving average is $11.71 and its 200 day moving average is $14.23. The firm has a market cap of $1.21 billion, a PE ratio of -2.96 and a beta of 1.16. Dyne Therapeutics has a one year low of $6.36 and a one year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.17). Research analysts predict that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Raymond James Financial Inc. purchased a new position in Dyne Therapeutics in the 4th quarter valued at $2,340,000. Schroder Investment Management Group boosted its holdings in shares of Dyne Therapeutics by 63.3% in the fourth quarter. Schroder Investment Management Group now owns 147,002 shares of the company’s stock valued at $3,477,000 after acquiring an additional 56,961 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Dyne Therapeutics by 4.2% during the first quarter. Rhumbline Advisers now owns 133,627 shares of the company’s stock worth $1,398,000 after acquiring an additional 5,383 shares during the period. Wells Fargo & Company MN raised its holdings in Dyne Therapeutics by 54.5% during the fourth quarter. Wells Fargo & Company MN now owns 38,754 shares of the company’s stock worth $913,000 after purchasing an additional 13,677 shares in the last quarter. Finally, Swiss National Bank lifted its position in Dyne Therapeutics by 3.3% in the fourth quarter. Swiss National Bank now owns 108,600 shares of the company’s stock valued at $2,559,000 after purchasing an additional 3,500 shares during the period. 96.68% of the stock is currently owned by institutional investors and hedge funds.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.